Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice. Data collected in the German BIKER registry were analyzed in patients with polyJIA who sta...
Saved in:
Published in | Arthritis research & therapy Vol. 18; no. 1; p. 272 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
24.11.2016
BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice.
Data collected in the German BIKER registry were analyzed in patients with polyJIA who started treatment with approved biologics, adalimumab, etanercept or tocilizumab, from 2011 to 2015. Baseline patient characteristics, treatment response, safety and drug survival were compared.
Two hundred thirty-six patient started adalimumab, 419 etanercept and 74 tocilizumab, with differences in baseline patient characteristics. Baseline Juvenile Disease Activity Score (JADAS)10 (mean ± SD) in the adalimumab/etanercept/tocilizumab cohorts was 12.1+/-7.6, 13.8 ± 7.1 and 15.1 ± 7.4, respectively (adalimumab vs etanercept, p = 0.01), and Childhood Health Assessment Questionnaire (CHAQ)-disability index scores was 0.43 ± 0.58, 0.59 ± 0.6 and 0.63 ± 0.55, respectively (adalimumab vs etanercept, p < 0.001). Uveitis history was more frequent in the adalimumab cohort (OR 5.73; p < 0.001). Balanced patients' samples were obtained by a generalized propensity score to adjust for baseline differences. Pediatric ACR30/50/70/90 criterion improvement after 3 months treatment was achieved by 68%/60%/42%/24% in the etanercept cohort, 67%/59%/43%/27% in the adalimumab cohort and 61%/52%/35%/26% in the tocilizumab cohort. At 24 months, JADAS minimal disease activity was achieved in 52.4%/61.3%/52.4% and JADAS remission in 27.9%/34.8%/27.9% patients in the adalimumab/etanercept/tocilizumab cohorts, respectively. Etanercept was used in 95.5% of patients as a first biologic, adalimumab in 50.8% and tocilizumab in 20.2%. There were no important differences in efficacy between first-line and second-line use of biologics. In total 60.4%/49.4%/31.1% patients discontinued adalimumab/etanercept/tocilizumab, respectively (HR for adalimumab 1.67; p < 0.001; HR for tocilizumab 0.35; p = 0.001). Drug survival rates did not differ significantly in patients on biologic monotherapy compared with combination therapy with methotrexate. Over 4 years observation under etanercept/adalimumab/tocilizumab, 996/386/103 adverse events, and 148/119/26 serious adverse events, respectively, were reported.
In clinical practice, etanercept is most frequently used as first-line biologic. Adalimumab/etanercept/tocilizumab showed comparable efficacy toward polyJIA. Overall, tolerance was acceptable. Interestingly, compliance was highest with tocilizumab and lowest with adalimumab. This study provides the first indication for the comparison of different biologic agents in polyarticular JIA based on observational study data with all their weaknesses and demonstrates the need for well-controlled head-to-head studies for confirmation. |
---|---|
AbstractList | Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice.
Data collected in the German BIKER registry were analyzed in patients with polyJIA who started treatment with approved biologics, adalimumab, etanercept or tocilizumab, from 2011 to 2015. Baseline patient characteristics, treatment response, safety and drug survival were compared.
Two hundred thirty-six patient started adalimumab, 419 etanercept and 74 tocilizumab, with differences in baseline patient characteristics. Baseline Juvenile Disease Activity Score (JADAS)10 (mean ± SD) in the adalimumab/etanercept/tocilizumab cohorts was 12.1+/-7.6, 13.8 ± 7.1 and 15.1 ± 7.4, respectively (adalimumab vs etanercept, p = 0.01), and Childhood Health Assessment Questionnaire (CHAQ)-disability index scores was 0.43 ± 0.58, 0.59 ± 0.6 and 0.63 ± 0.55, respectively (adalimumab vs etanercept, p < 0.001). Uveitis history was more frequent in the adalimumab cohort (OR 5.73; p < 0.001). Balanced patients' samples were obtained by a generalized propensity score to adjust for baseline differences. Pediatric ACR30/50/70/90 criterion improvement after 3 months treatment was achieved by 68%/60%/42%/24% in the etanercept cohort, 67%/59%/43%/27% in the adalimumab cohort and 61%/52%/35%/26% in the tocilizumab cohort. At 24 months, JADAS minimal disease activity was achieved in 52.4%/61.3%/52.4% and JADAS remission in 27.9%/34.8%/27.9% patients in the adalimumab/etanercept/tocilizumab cohorts, respectively. Etanercept was used in 95.5% of patients as a first biologic, adalimumab in 50.8% and tocilizumab in 20.2%. There were no important differences in efficacy between first-line and second-line use of biologics. In total 60.4%/49.4%/31.1% patients discontinued adalimumab/etanercept/tocilizumab, respectively (HR for adalimumab 1.67; p < 0.001; HR for tocilizumab 0.35; p = 0.001). Drug survival rates did not differ significantly in patients on biologic monotherapy compared with combination therapy with methotrexate. Over 4 years observation under etanercept/adalimumab/tocilizumab, 996/386/103 adverse events, and 148/119/26 serious adverse events, respectively, were reported.
In clinical practice, etanercept is most frequently used as first-line biologic. Adalimumab/etanercept/tocilizumab showed comparable efficacy toward polyJIA. Overall, tolerance was acceptable. Interestingly, compliance was highest with tocilizumab and lowest with adalimumab. This study provides the first indication for the comparison of different biologic agents in polyarticular JIA based on observational study data with all their weaknesses and demonstrates the need for well-controlled head-to-head studies for confirmation. Background Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice. Methods Data collected in the German BIKER registry were analyzed in patients with polyJIA who started treatment with approved biologics, adalimumab, etanercept or tocilizumab, from 2011 to 2015. Baseline patient characteristics, treatment response, safety and drug survival were compared. Results Two hundred thirty-six patient started adalimumab, 419 etanercept and 74 tocilizumab, with differences in baseline patient characteristics. Baseline Juvenile Disease Activity Score (JADAS)10 (mean ± SD) in the adalimumab/etanercept/tocilizumab cohorts was 12.1+/-7.6, 13.8 ± 7.1 and 15.1 ± 7.4, respectively (adalimumab vs etanercept, p = 0.01), and Childhood Health Assessment Questionnaire (CHAQ)-disability index scores was 0.43 ± 0.58, 0.59 ± 0.6 and 0.63 ± 0.55, respectively (adalimumab vs etanercept, p < 0.001). Uveitis history was more frequent in the adalimumab cohort (OR 5.73; p < 0.001). Balanced patients' samples were obtained by a generalized propensity score to adjust for baseline differences. Pediatric ACR30/50/70/90 criterion improvement after 3 months treatment was achieved by 68%/60%/42%/24% in the etanercept cohort, 67%/59%/43%/27% in the adalimumab cohort and 61%/52%/35%/26% in the tocilizumab cohort. At 24 months, JADAS minimal disease activity was achieved in 52.4%/61.3%/52.4% and JADAS remission in 27.9%/34.8%/27.9% patients in the adalimumab/etanercept/tocilizumab cohorts, respectively. Etanercept was used in 95.5% of patients as a first biologic, adalimumab in 50.8% and tocilizumab in 20.2%. There were no important differences in efficacy between first-line and second-line use of biologics. In total 60.4%/49.4%/31.1% patients discontinued adalimumab/etanercept/tocilizumab, respectively (HR for adalimumab 1.67; p < 0.001; HR for tocilizumab 0.35; p = 0.001). Drug survival rates did not differ significantly in patients on biologic monotherapy compared with combination therapy with methotrexate. Over 4 years observation under etanercept/adalimumab/tocilizumab, 996/386/103 adverse events, and 148/119/26 serious adverse events, respectively, were reported. Conclusions In clinical practice, etanercept is most frequently used as first-line biologic. Adalimumab/etanercept/tocilizumab showed comparable efficacy toward polyJIA. Overall, tolerance was acceptable. Interestingly, compliance was highest with tocilizumab and lowest with adalimumab. This study provides the first indication for the comparison of different biologic agents in polyarticular JIA based on observational study data with all their weaknesses and demonstrates the need for well-controlled head-to-head studies for confirmation. |
ArticleNumber | 272 |
Audience | Academic |
Author | Horneff, Gerd Kuemmerle-Deschner, Jasmin Hospach, Anton Klein, Ariane Minden, Kirsten Weller-Heinemann, Frank Haas, Johannes-Peter Huppertz, Hans-Iko Klotsche, Jens |
Author_xml | – sequence: 1 givenname: Gerd surname: Horneff fullname: Horneff, Gerd email: g.horneff@asklepios.com organization: Department of Pediatrics, Centre of General Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, 53757, Sankt Augustin, Germany. g.horneff@asklepios.com – sequence: 2 givenname: Ariane surname: Klein fullname: Klein, Ariane organization: Department of Pediatrics, Centre of General Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, 53757, Sankt Augustin, Germany – sequence: 3 givenname: Jens surname: Klotsche fullname: Klotsche, Jens organization: German Rheumatism Research Centre Berlin, and Children's University Hospital Charité, Berlin, Germany – sequence: 4 givenname: Kirsten surname: Minden fullname: Minden, Kirsten organization: German Rheumatism Research Centre Berlin, and Children's University Hospital Charité, Berlin, Germany – sequence: 5 givenname: Hans-Iko surname: Huppertz fullname: Huppertz, Hans-Iko organization: Prof Hess Children's Hospital, Bremen, Germany – sequence: 6 givenname: Frank surname: Weller-Heinemann fullname: Weller-Heinemann, Frank organization: Prof Hess Children's Hospital, Bremen, Germany – sequence: 7 givenname: Jasmin surname: Kuemmerle-Deschner fullname: Kuemmerle-Deschner, Jasmin organization: Department of Pediatrics, University of Tuebingen, 72076, Tuebingen, Germany – sequence: 8 givenname: Johannes-Peter surname: Haas fullname: Haas, Johannes-Peter organization: German Centre for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany – sequence: 9 givenname: Anton surname: Hospach fullname: Hospach, Anton organization: Department of Pediatrics, Section of Rheumatology, Olgahospital, Klinikum, Stuttgart, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27881144$$D View this record in MEDLINE/PubMed |
BookMark | eNptUttqHSEUlZLSXNoP6EsR-ppJvc2M81IIh94g0Jf2WRzdnuNhRqfqpKQf1W-sh5OmCRRBt-611t7qOkcnIQZA6DUlV5TK7l2mnPRtQ2jXUNqThj9DZ1T0sul4x04exafoPOc9IYwNTLxAp6yXklIhztDvTZwXnXyOAUeHSwJdZggFJ8hLDBkuazT7nH0FJF0A62CxTesWa7uDBMEA9gEvcbrTqXizTjrh_XoLwU81Y31cdNl5g2t2l3zxGdcDX0vkYzWw-KcvOwxFB0gGlnJZpfXk53XWI44Jl2j85H8dti_Rc6enDK_u1wv0_eOHb5vPzc3XT1821zeNEYMojRu7jhgmzMBH4oizsmfWUTO0FqSWHEY-dGI8zJwYQcw4cCbpKF2vYbCGX6D3R91lHWewprab9KSW5Ged7lTUXj3NBL9T23irWsoYoawKvL0XSPHHCrmofVxTqD0rKkXH2p4M5B9qqydQPrhYxUx9bqOuRU_Z0FHSVtTVf1B12PozplrC1ad-SqBHgkkx5wTuoXFK1ME56ugcVZ2jDs5RvHLePL7xA-OvVfgfFmnF-w |
CitedBy_id | crossref_primary_10_1097_ICO_0000000000001467 crossref_primary_10_1016_j_jbspin_2018_08_003 crossref_primary_10_1002_acr_24853 crossref_primary_10_1007_s10067_018_4367_9 crossref_primary_10_1080_14712598_2019_1595578 crossref_primary_10_1002_art_42037 crossref_primary_10_1016_j_revmed_2018_03_001 crossref_primary_10_1016_j_rhum_2019_11_014 crossref_primary_10_1007_s10067_018_4071_9 crossref_primary_10_1080_14740338_2020_1763300 crossref_primary_10_1002_acr2_11444 crossref_primary_10_1055_a_1252_5281 crossref_primary_10_1186_s42358_020_00154_4 crossref_primary_10_15690_vsp_v17i3_1889 crossref_primary_10_1186_s12969_017_0206_9 crossref_primary_10_1002_acr_25339 crossref_primary_10_1136_rmdopen_2020_001208 crossref_primary_10_1002_acr_23870 crossref_primary_10_1093_rheumatology_keac587 crossref_primary_10_5863_1551_6776_26_2_157 crossref_primary_10_47360_1995_4484_2023_369_376 crossref_primary_10_1016_S2665_9913_20_30058_8 crossref_primary_10_1055_a_1582_4635 crossref_primary_10_1186_s12969_019_0358_x crossref_primary_10_1186_s12969_022_00763_x crossref_primary_10_1093_rheumatology_kez291 crossref_primary_10_1055_a_2297_1691 crossref_primary_10_1097_BOR_0000000000000417 crossref_primary_10_1002_acr_23709 crossref_primary_10_1016_j_autrev_2017_07_014 crossref_primary_10_1186_s12969_023_00798_8 crossref_primary_10_1007_s10067_017_3672_z crossref_primary_10_1080_14740338_2019_1632288 crossref_primary_10_1186_s13023_020_1324_x crossref_primary_10_15690_vsp_v17i5_1954 crossref_primary_10_1038_s41598_021_95252_8 crossref_primary_10_1177_2326409818796854 crossref_primary_10_1093_rheumatology_kez683 crossref_primary_10_1080_14397595_2019_1574697 crossref_primary_10_1186_s13075_018_1780_z crossref_primary_10_1186_s12969_019_0362_1 crossref_primary_10_54133_ajms_v5i_232 crossref_primary_10_1093_rheumatology_keaa877 crossref_primary_10_1002_art_41043 crossref_primary_10_2147_TCRM_S375890 crossref_primary_10_1002_art_40884 crossref_primary_10_1093_rheumatology_keab354 crossref_primary_10_1007_s00393_019_0645_4 crossref_primary_10_1080_21678707_2018_1433032 crossref_primary_10_15690_vsp_v17i2_1880 crossref_primary_10_3899_jrheum_200437 crossref_primary_10_1136_rmdopen_2022_002359 crossref_primary_10_1186_s13075_022_02968_7 crossref_primary_10_1186_s43055_023_01167_x crossref_primary_10_1002_acr2_11325 crossref_primary_10_1007_s00296_020_04774_3 crossref_primary_10_1080_14397595_2017_1349059 crossref_primary_10_1186_s13075_021_02492_0 crossref_primary_10_1136_archdischild_2018_315528 crossref_primary_10_1093_rheumatology_kead490 crossref_primary_10_3899_jrheum_201331 crossref_primary_10_1016_j_ejr_2020_02_011 crossref_primary_10_1093_rheumatology_kez309 |
Cites_doi | 10.4081/reumatismo.2013.682 10.1002/art.1780371209 10.1002/art.38741 10.1517/14656560903386300 10.3899/jrheum.140472 10.1136/ard.2007.087411 10.1053/gast.2001.28674 10.1002/acr.22613 10.1056/NEJM199204163261602 10.1002/art.34343 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R 10.1136/ard.2007.087593 10.1002/acr.20460 10.1093/rheumatology/ket170 10.1002/art.24516 10.1055/s-0031-1287837 10.1093/rheumatology/keq361 10.1136/ard.2010.143347 10.1136/annrheumdis-2014-205351 10.1056/NEJM200003163421103 10.1002/art.27670 10.1186/1745-6215-15-14 10.1002/art.39197 10.1056/NEJMoa0706290 10.1002/art.34373 10.1136/ard.2003.014886 10.1136/annrheumdis-2013-204641 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2016 BioMed Central Ltd. Copyright BioMed Central 2016 The Author(s). 2016 |
Copyright_xml | – notice: COPYRIGHT 2016 BioMed Central Ltd. – notice: Copyright BioMed Central 2016 – notice: The Author(s). 2016 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 5PM |
DOI | 10.1186/s13075-016-1170-3 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
DatabaseTitleList | MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: ProQuest Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1478-6362 |
ExternalDocumentID | 4271153061 A471296105 10_1186_s13075_016_1170_3 27881144 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GeographicLocations | Germany |
GeographicLocations_xml | – name: Germany |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- -5E -5G -A0 -BR .GJ 0R~ 23N 2WC 3V. 4.4 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ ABUWG ACGFS ACJQM ACRMQ ADBBV ADINQ ADUKV AEGXH AENEX AFKRA AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK E3Z EBD EBLON ECM EIF EJD EMOBN F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ IAO IHR INH INR ITC KQ8 M1P NPM O5R O5S O9- PGMZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 U2A UKHRP WOQ Z7U AAYXX AFPKN CITATION ABVAZ AFGXO AFNRJ ZA5 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 5PM |
ID | FETCH-LOGICAL-c494t-fb660c24c93b0f0fd872df1c95de8a83eb3964bb39630c40cb93281b8f7ae9dc3 |
IEDL.DBID | RPM |
ISSN | 1478-6362 1478-6354 |
IngestDate | Tue Sep 17 20:59:08 EDT 2024 Thu Oct 10 20:16:00 EDT 2024 Thu Feb 22 23:32:42 EST 2024 Wed Jan 10 04:15:51 EST 2024 Thu Sep 12 17:57:07 EDT 2024 Wed Oct 23 09:55:31 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Drug surveillance Etanercept Adalimumab Tocilizumab JADAS Juvenile idiopathic arthritis |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c494t-fb660c24c93b0f0fd872df1c95de8a83eb3964bb39630c40cb93281b8f7ae9dc3 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122012/ |
PMID | 27881144 |
PQID | 1846257090 |
PQPubID | 42876 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5122012 proquest_journals_1846257090 gale_infotracmisc_A471296105 gale_infotracacademiconefile_A471296105 crossref_primary_10_1186_s13075_016_1170_3 pubmed_primary_27881144 |
PublicationCentury | 2000 |
PublicationDate | 2016-11-24 |
PublicationDateYYYYMMDD | 2016-11-24 |
PublicationDate_xml | – month: 11 year: 2016 text: 2016-11-24 day: 24 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Arthritis research & therapy |
PublicationTitleAlternate | Arthritis Res Ther |
PublicationYear | 2016 |
Publisher | BioMed Central Ltd BioMed Central |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
References | G Horneff (1170_CR9) 2009; 68 CA Wallace (1170_CR30) 2012; 64 HI Brunner (1170_CR13) 2015; 74 M Romano (1170_CR24) 2013; 65 N Ruperto (1170_CR10) 2010; 62 H Schmeling (1170_CR12) 2014; 66 P Tynjälä (1170_CR31) 2011; 70 RE Petty (1170_CR1) 2004; 31 1170_CR23 G Horneff (1170_CR8) 2004; 63 G Horneff (1170_CR22) 2011; 50 EH Giannini (1170_CR17) 1997; 40 J Anink (1170_CR29) 2013; 52 R Davies (1170_CR25) 2015; 67 WJ Sandborn (1170_CR27) 2001; 121 T Beukelman (1170_CR5) 2011; 63 FH Prince (1170_CR7) 2009; 68 I Foeldvari (1170_CR28) 2015; 67 G Horneff (1170_CR15) 2004; 63 S Danner (1170_CR2) 2006; 33 A Klein (1170_CR14) 2009; 10 EH Giannini (1170_CR3) 1992; 326 DJ Lovell (1170_CR6) 2000; 342 DJ Lovell (1170_CR21) 2008; 359 MH Otten (1170_CR20) 2015; 74 1170_CR11 G Dueckers (1170_CR4) 2011; 223 D Barthel (1170_CR26) 2015; 42 A Consolaro (1170_CR16) 2009; 61 A Consolaro (1170_CR18) 2012; 64 G Singh (1170_CR19) 1994; 37 |
References_xml | – ident: 1170_CR23 – volume: 65 start-page: 278 year: 2013 ident: 1170_CR24 publication-title: Reumatismo doi: 10.4081/reumatismo.2013.682 contributor: fullname: M Romano – volume: 33 start-page: 1377 year: 2006 ident: 1170_CR2 publication-title: J Rheumatol contributor: fullname: S Danner – volume: 37 start-page: 1761 year: 1994 ident: 1170_CR19 publication-title: Arthritis Rheum doi: 10.1002/art.1780371209 contributor: fullname: G Singh – volume: 66 start-page: 2580 year: 2014 ident: 1170_CR12 publication-title: Arthritis Rheumatol doi: 10.1002/art.38741 contributor: fullname: H Schmeling – volume: 10 start-page: 3049 year: 2009 ident: 1170_CR14 publication-title: Expert Opin Pharmacother doi: 10.1517/14656560903386300 contributor: fullname: A Klein – volume: 42 start-page: 2160 year: 2015 ident: 1170_CR26 publication-title: J Rheumatol doi: 10.3899/jrheum.140472 contributor: fullname: D Barthel – volume: 68 start-page: 635 year: 2009 ident: 1170_CR7 publication-title: Ann Rheum Dis doi: 10.1136/ard.2007.087411 contributor: fullname: FH Prince – volume: 121 start-page: 1088 year: 2001 ident: 1170_CR27 publication-title: Gastroenterology doi: 10.1053/gast.2001.28674 contributor: fullname: WJ Sandborn – volume: 67 start-page: 1529 year: 2015 ident: 1170_CR28 publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.22613 contributor: fullname: I Foeldvari – volume: 326 start-page: 1043 year: 1992 ident: 1170_CR3 publication-title: N Engl J Med doi: 10.1056/NEJM199204163261602 contributor: fullname: EH Giannini – volume: 64 start-page: 2012 year: 2012 ident: 1170_CR30 publication-title: Arthritis Rheum doi: 10.1002/art.34343 contributor: fullname: CA Wallace – volume: 40 start-page: 1202 year: 1997 ident: 1170_CR17 publication-title: Arthritis Rheum doi: 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R contributor: fullname: EH Giannini – volume: 68 start-page: 519 year: 2009 ident: 1170_CR9 publication-title: Ann Rheum Dis doi: 10.1136/ard.2007.087593 contributor: fullname: G Horneff – volume: 63 start-page: 465 year: 2011 ident: 1170_CR5 publication-title: Arthritis Care Res doi: 10.1002/acr.20460 contributor: fullname: T Beukelman – volume: 31 start-page: 390 year: 2004 ident: 1170_CR1 publication-title: J Rheumatol contributor: fullname: RE Petty – volume: 52 start-page: 1674 year: 2013 ident: 1170_CR29 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/ket170 contributor: fullname: J Anink – volume: 61 start-page: 658 year: 2009 ident: 1170_CR16 publication-title: Arthritis Rheum doi: 10.1002/art.24516 contributor: fullname: A Consolaro – volume: 223 start-page: 386 year: 2011 ident: 1170_CR4 publication-title: Klin Padiatr doi: 10.1055/s-0031-1287837 contributor: fullname: G Dueckers – volume: 50 start-page: 230 year: 2011 ident: 1170_CR22 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keq361 contributor: fullname: G Horneff – volume: 70 start-page: 1605 year: 2011 ident: 1170_CR31 publication-title: Ann Rheum Dis doi: 10.1136/ard.2010.143347 contributor: fullname: P Tynjälä – volume: 74 start-page: 1110 year: 2015 ident: 1170_CR13 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2014-205351 contributor: fullname: HI Brunner – volume: 342 start-page: 763 year: 2000 ident: 1170_CR6 publication-title: N Engl J Med doi: 10.1056/NEJM200003163421103 contributor: fullname: DJ Lovell – volume: 62 start-page: 3131 year: 2010 ident: 1170_CR10 publication-title: Arthritis Rheum doi: 10.1002/art.27670 contributor: fullname: N Ruperto – ident: 1170_CR11 doi: 10.1186/1745-6215-15-14 – volume: 67 start-page: 2487 year: 2015 ident: 1170_CR25 publication-title: Arthritis Rheumatol doi: 10.1002/art.39197 contributor: fullname: R Davies – volume: 359 start-page: 810 year: 2008 ident: 1170_CR21 publication-title: N Engl J Med doi: 10.1056/NEJMoa0706290 contributor: fullname: DJ Lovell – volume: 64 start-page: 2366 year: 2012 ident: 1170_CR18 publication-title: Arthritis Rheum doi: 10.1002/art.34373 contributor: fullname: A Consolaro – volume: 63 start-page: 1638 year: 2004 ident: 1170_CR15 publication-title: Ann Rheum Dis doi: 10.1136/ard.2003.014886 contributor: fullname: G Horneff – volume: 74 start-page: 1379 year: 2015 ident: 1170_CR20 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-204641 contributor: fullname: MH Otten – volume: 63 start-page: 1638 year: 2004 ident: 1170_CR8 publication-title: Ann Rheum Dis doi: 10.1136/ard.2003.014886 contributor: fullname: G Horneff |
SSID | ssj0022924 |
Score | 2.5042896 |
Snippet | Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept,... Background Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab,... |
SourceID | pubmedcentral proquest gale crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 272 |
SubjectTerms | Adalimumab Adalimumab - therapeutic use Adolescent Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arthritis Arthritis, Juvenile - drug therapy Child Comparative analysis Drug therapy Etanercept Etanercept - therapeutic use Female Health aspects Humans Juvenile arthritis Male Medication Adherence - statistics & numerical data Patient compliance Registries Remission Induction Treatment Outcome |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtAqWXkr6dpkWHQqHExJbkh04hCQmhkFBKA7kZWSN3XRJ7u49D-qP6GztjaZ24h17EGhnL7IxmvhmN52PsI-D-d5DJWGufuknjEmRGA6SNMCUMZDAXl_n5lfpynV2HhNsylFVubOJgqKG3lCM_wEgkJ8Y1nRzOf8XEGkWnq4FC4zHbFqmiY9rt49PLr9_GkEtoT2urMFZC16rCuWZa5gdLtN4FFa7l8cC-Iiee6V_7_MBBTYsnH3ijsx32LMBIfuTl_pw9ct0L9uQiHJS_ZH9ORn5B3jd8LCfnC18T6_bxF4qYcmWcukVw0wGHxfoHNzDznwDytuPz_uZuUC6qVuU_12ga0YzwFtp-4DK2HGdnQ2MkHlq0Lv1qDjjleLlD9OmLZ_bx0Yj6b9e3pub9gq9QL27a33T5il2dnX4_OY8DNUNslVaruKnzPLFCWS3rpEkaKAsBTWp1Bq40pcQQXeeqplEmViW2RpyICLlsCuM0WPmabXV9594ybqxVAKpMG6NVhkOmjMwLCVktCg0uYp83YqnmvgNHNUQuZV55GVZUpUYyrGTEPpHgKtqdKB1rwkcGuBT1uaqO0BcLjZAxi9je5E78y-10eiP6KuzqZXWvgxF747VgfCVBffkxOo1YMdGP8Qbq4z2d6drZ0M8bMRfCMLH7_yXfsafCK2ss1B7bWi3W7j0ColX9IWj9X71kDwY priority: 102 providerName: ProQuest |
Title | Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27881144 https://www.proquest.com/docview/1846257090 https://pubmed.ncbi.nlm.nih.gov/PMC5122012 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZJCqWX0nedpsscCoUSZ21Jfui4XRJCYUMoXdibkSW567JrL_s4ND-qv7EjyV7iHnsRNpItoZnRzEifZgj5pFH-jU5YKITfuonDXLPEFjquqMy1SwYzu0tv5_zbIlmckKS_C-NA-6qsr5rV-qqplw5buVmrcY8TG9_PpqikUG_R8Sk5zRjrXfTOy6LCZ7Ll6B6hNuXdUWacp-MdLtiZxaqloUu4YpPoUBtPHb2KgV76d3V-pJ6G0MlHuujmBXneGZEw8YN9SU5M84o8nXXH5K_Jn-kxuyC0FRzB5LD1iFhziU9IYLtTBjZWBMhGg94efoLUS38BEOoGNu3qt5sRi1WFXwdcGHERgVrXrctkrABrly4sEnQBWne-N6PB7vCCQdvTQ2cu8ddo868Pa1lCu4U9csWqfrCvb8j85vrH9DbsEjOEigu-D6syTSNFuRKsjKqo0nlGdRUrkWiTy5yhgy5SXtqSRYpHqkQrEe3jvMqkEVqxt-SsaRvznoBUimvN87iSgidYJFyyNGM6KWkmtAnIl54sxcbH3yic35KnhSdnYTFqlpwFC8hnS7jCyiZSR8nuigF2ZaNcFRPUxFSgwZgE5GLQEqdcDat70hedTO8K9IVTm_NPRAF557ngOKSeiwKSDfjj2MBG8R7WIHO7aN4dM5__95cfyDPqWTqk_IKc7bcH8xEtpX05QvlYZCPy5Ov13f33kdtvGDlpwXJOJ38B3Jga1w |
link.rule.ids | 230,315,733,786,790,870,891,12083,21416,27955,27956,31752,33777,43343,43838,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSMAF8SZQwAckJNSoie0k9glVFdUC3Z5aaW-WYzvdoDZZ9nGAH8VvZCb2bhsOXKyNHMXRznjmm_FkPkI-ONj_3hU8VSqkbvJUOl7g4PKGGekGMpjpWTm5EN9mxSwm3FaxrHJrEwdD7XqLOfJDiERKZFxT2efFzxRZo_B0NVJo3CX3BOcC9bya3QRcTAVSWwGREjhWEU81c1kersB2V1i2VqYD9wof-aV_rfMt9zQunbzli04ek0cRRNKjIPUn5I7vnpL703hM_oz8Od6xC9K-obticroMFbH-AH6BgDFTRrFXBDWdo265uaTGzcMHgLTt6KK_-jWoFtaq0h8bMIxgRGjr2n5gMrYUZudDWyQaG7SuwmreUczwUg_YM5TOHMCjAfNfb65NTfslXYNWXLW_8fI5uTj5cn48SSMxQ2qFEuu0qcsys0xYxeusyRonK-aa3KrCeWkkhwBdlaLGkWdWZLYGlAj4WDaV8cpZ_oLsdX3nXxFqrBXOCZk3RokChkIYXlbcFTWrlPMJ-bQVi16E_ht6iFtkqYMMNdaooQw1T8hHFJzGvQnSsSZ-YgBLYZcrfQSemCkAjEVC9kd3wl9ux9Nb0eu4p1f6RgMT8jJowe6VGHblh9g0IdVIP3Y3YBfv8UzXzodu3oC4AISx1_9f8j15MDmfnurTr2ff35CHLChuysQ-2VsvN_4tQKN1_W7Q_78S7xCN |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagSBWXstNAAR-QkFAzSWxn8bEaGJVlqh6oVHGxEtthAjPJaCY50B_Fb-TZTkaTHnuxEtmJs3xvc768h9B7BfKvVUx9zt3STeRnisamUVFJ8kzZYjDzi-T8in29jq_3Sn1Z0r4sqkm9XE3qamG5leuVDAaeWHA5n4KRArtFgrUqg_voAcgsSYdAvY-1CHf1bBkESWBTWf9BM8qSYAtqOzWMtcS3ZVdMKR1isqpDbDGyTrd19J6RGhMo9yzS7BH6OdyLI6L8mXRtMZE3t9I83ulmH6Oj3k_FZ27IE3RP10_R4bz_Ev8M_ZvuChjipsQ7vjreONKtPoUtwJBZjMMmHQXOa4XVpvuFc7Vw_xjiqsbrZvnXXoehw-LfHehe0FO4UlVjiyVLDL0Lm3kJ9zlgt242rbBZRMYa3FvHzjmFU0NYsepWeYGbDW4BeMvqxuw-R1ezzz-m535f-8GXjLPWL4skCSVhktMiLMNSZSlRZSR5rHSWZ1QXlCesMC0NJQtlAY4ouOBZmeaaK0lfoIO6qfUxwrmUTCmWRWXOWQxNzHKapFTFBUm50h76OLxzsXYpPoQNjbJEOKwIQ4MzWBHUQx8MKoQRf3j1Mu__YoCpTCItcQbGnnDwSWMPnYxGwiOX4-4BV6JXG1sB4XZiygry0EMvHcR2lzRA1EPpCHy7ASZR-LgHIGUThvcQenXnI9-hw8tPM_H9y8W31-ghcaLjE3aCDtpNp9-AX9YWb60E_gdaATrb |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+treatment+response%2C+remission+rate+and+drug+adherence+in+polyarticular+juvenile+idiopathic+arthritis+patients+treated+with+etanercept%2C+adalimumab+or+tocilizumab&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Horneff%2C+Gerd&rft.au=Klein%2C+Ariane&rft.au=Klotsche%2C+Jens&rft.au=Minden%2C+Kirsten&rft.date=2016-11-24&rft.pub=BioMed+Central&rft.issn=1478-6354&rft.eissn=1478-6362&rft.volume=18&rft_id=info:doi/10.1186%2Fs13075-016-1170-3&rft_id=info%3Apmid%2F27881144&rft.externalDBID=PMC5122012 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon |